Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1959 1
1970 1
1980 1
1981 1
1983 1
1984 1
1987 1
1992 1
1993 1
1994 1
1995 1
1996 2
1997 7
1998 2
1999 6
2000 6
2001 23
2002 10
2003 11
2004 5
2005 8
2006 11
2007 16
2008 19
2009 20
2010 29
2011 25
2012 26
2013 41
2014 54
2015 59
2016 19
2017 17
2018 17
2019 19
2020 28
2021 22
2022 13
2023 11
2024 14
2025 9

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

487 results

Results by year

Filters applied: . Clear all
Page 1
Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses.
Pfister C, Gravis G, Fléchon A, Soulié M, Guy L, Laguerre B, Mottet N, Joly F, Allory Y, Harter V, Culine S; VESPER Trial Investigators. Pfister C, et al. Among authors: soulie m. Eur Urol. 2021 Feb;79(2):214-221. doi: 10.1016/j.eururo.2020.08.024. Epub 2020 Aug 28. Eur Urol. 2021. PMID: 32868138 Clinical Trial.
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial.
Pfister C, Gravis G, Fléchon A, Chevreau C, Mahammedi H, Laguerre B, Guillot A, Joly F, Soulié M, Allory Y, Harter V, Culine S; VESPER Trial Investigators. Pfister C, et al. Among authors: soulie m. J Clin Oncol. 2022 Jun 20;40(18):2013-2022. doi: 10.1200/JCO.21.02051. Epub 2022 Mar 7. J Clin Oncol. 2022. PMID: 35254888 Clinical Trial.
Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study.
Pfister C, Gravis G, Flechon A, Chevreau C, Mahammedi H, Laguerre B, Guillot A, Joly F, Soulie M, Allory Y, Harter V, Culine S; VESPER Trial Investigators. Pfister C, et al. Among authors: soulie m. Lancet Oncol. 2024 Feb;25(2):255-264. doi: 10.1016/S1470-2045(23)00587-9. Epub 2023 Dec 21. Lancet Oncol. 2024. PMID: 38142702 Clinical Trial.
Prostatectomie totale par voies ouvertes et mini-invasives (étude comparative prospective Propenlap) : résultats carcinologiques.
Salomon L, Bastuji-Garin S, Mazerolles C, Devonec M, Soulie M, Benoit G, Rischmann P, Decaussin-Petrucci M, Mottet N, Gasman D, Fromont-Hankard G, Irani J, De la Taille A, Zerbib M, Ferlicot S, Comperat E, Vaesen C, Beuvon F, Lebret T, Boutin E, Mege-Lechevallier F, Dore B, Radulescu C, Paoletti M, Shar A, Colombel M, Lechevallier E. Salomon L, et al. Among authors: soulie m. Prog Urol. 2015 Nov;25(13):792-3. doi: 10.1016/j.purol.2015.08.153. Prog Urol. 2015. PMID: 26544348 French. No abstract available.
Sur-traitement et sous traitement du cancer de la prostate en Midi-Pyrénées.
Lunardi P, Beauval J, Gamé X, Roumiguié M, Thoulouzan M, Doumerc N, Huyghe E, Soulié M, Rischmann P, Grosclaude P, Malavaud B. Lunardi P, et al. Among authors: soulie m. Prog Urol. 2015 Nov;25(13):756. doi: 10.1016/j.purol.2015.08.083. Prog Urol. 2015. PMID: 26544279 French. No abstract available.
Résultats économiques de Propenlap, étude prospective multicentrique comparant les voies ouvertes et mini-invasives de la prostatectomie totale.
Durand-Zaleski I, Rabetrano H, Devonec M, Mandron E, Soulie M, De la Taille A, Benoit G, Mottet N, Gasman D, Dore B, Zerbib M, Vaessen C, Irani J, Lebret T, Colombel M, Lechevallier E, Bastuji-Garin S, Allory Y, Abbou C, Rischmann P, Salomon L. Durand-Zaleski I, et al. Among authors: soulie m. Prog Urol. 2015 Nov;25(13):742. doi: 10.1016/j.purol.2015.08.054. Prog Urol. 2015. PMID: 26544250 French. No abstract available.
Le cancer de vessie chez le sujet jeune, une étude de population française.
Compérat E, Larré S, Neuzillet Y, Vordos D, Soulié M, Azzouzi A, Pignot G, Durand X, Quintens H, Houede N, Jeglischi S, El Bakri A, Bigot P, Lebdai S, Rouprêt M, Pfister C. Compérat E, et al. Among authors: soulie m. Prog Urol. 2014 Nov;24(13):846. doi: 10.1016/j.purol.2014.08.140. Epub 2014 Oct 30. Prog Urol. 2014. PMID: 26461667 French. No abstract available.
Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial.
Sargos P, Chabaud S, Latorzeff I, Magné N, Benyoucef A, Supiot S, Pasquier D, Abdiche MS, Gilliot O, Graff-Cailleaud P, Silva M, Bergerot P, Baumann P, Belkacemi Y, Azria D, Brihoum M, Soulié M, Richaud P. Sargos P, et al. Among authors: soulie m. Lancet Oncol. 2020 Oct;21(10):1341-1352. doi: 10.1016/S1470-2045(20)30454-X. Lancet Oncol. 2020. PMID: 33002438 Clinical Trial.
487 results